Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ALT Relative to the S&P 500

ALT Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Altimmune, Inc. (NASD:ALT) seasonal charts above shows that a Buy Date of December 18 and a Sell Date of March 13 has resulted in a geometric average return of 17.68% above the benchmark rate of the S&P 500 Total Return Index over the past 19 years. This seasonal timeframe has shown positive results compared to the benchmark in 15 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 19 years by an average of 42.43% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company’s pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

To download ALT seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ALT